Balanced news tone
News Sentiment
COAG sentiment intelligence
Hemab Therapeutics Holdings, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
+22.7% over one week, +52.2% over four weeks, trend inactive, and materially above fair value.
Hemab Therapeutics (NASDAQ:COAG) Trading Down 3.8% - Should You Sell?
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Hemab Therapeutics (NASDAQ:COAG) Trading Down 3.8% - Should You Sell?
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 15 Jul 2026 16:26
- Source
- MarketBeat
Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 07:52
- Source
- Seeking Alpha
symbol__ Stock Quote Price and Forecast
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 15 Jul 2026 01:05
- Source
- CNN
Hemab Therapeutics reports positive Phase 2 sutacimig data
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 Jul 2026 16:28
- Source
- grafa.com
Hemab Advances Bleeding Disorder Pipeline
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 13:24
- Source
- Sahm
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 11:45
- Source
- GlobeNewswire
Hemab GT study finds 72% of patients 40+ still bleed weekly
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 11:45
- Source
- Stock Titan
Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $47
- Tone
- Positive 82/100
- Event
- Analyst action
- Published
- 14 Jul 2026 11:34
- Source
- 富途牛牛
H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $52
- Tone
- Positive 82/100
- Event
- Analyst action
- Published
- 14 Jul 2026 03:53
- Source
- Moomoo
Hemab Therapeutics' HMB-002 Well Suited for Type 1 Von Willebrand Disease, Wedbush Says
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 14:42
- Source
- MT Newswires
Hemab Therapeutics (NASDAQ:COAG) Earns Outperform Rating from Wedbush
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 13 Jul 2026 13:43
- Source
- MarketBeat
Hemab Therapeutics (NASDAQ:COAG) Price Target Raised to $52.00 at HC Wainwright
- Tone
- Positive 64/100
- Event
- Analyst action
- Published
- 13 Jul 2026 12:39
- Source
- MarketBeat
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Wedbush Raises Price Target on Hemab Therapeutics to $55 From $42, Keeps Outperform Rating
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 13 Jul 2026 10:54
- Source
- MT Newswires
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 10:28
- Source
- GlobeNewswire
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 13:00
- Source
- GlobeNewswire
Hemab brings nine bleeding-disorder studies to ISTH 2026 in Paris
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 07:00
- Source
- Stock Titan
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- TradingView
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 03:03
- Source
- MarketBeat
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 12:00
- Source
- GlobeNewswire
UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+
- Tone
- Positive 84/100
- Event
- Earnings
- Published
- 26 May 2026 07:00
- Source
- eciks.org
Goldman Sachs initiates Hemab Therapeutics stock with buy rating on rare disease drug potential
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 26 May 2026 07:00
- Source
- Investing.com
Hemab Therapeutics Reports First Quarter 2026 Financial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 May 2026 11:00
- Source
- GlobeNewswire
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- Quiver Quantitative
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Hemab Therapeutics (COAG) Stock Trends and Sentiment 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 May 2026 15:33
- Source
- MarketBeat
Hemab's stock market debut brings in $346.7M after banks buy more shares
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 04 May 2026 07:00
- Source
- Stock Titan